Literature DB >> 24523379

Paying twice: questions over high cost of cystic fibrosis drug developed with charitable funding.

Deborah Cohen1, James Raftery.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24523379     DOI: 10.1136/bmj.g1445

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  8 in total

1.  The pharmacokinetic interaction between ivacaftor and ritonavir in healthy volunteers.

Authors:  Anne Marie Liddy; Gavin McLaughlin; Susanne Schmitz; Deirdre M D'Arcy; Michael G Barry
Journal:  Br J Clin Pharmacol       Date:  2017-06-27       Impact factor: 4.335

Review 2.  Affordable orphan drugs: a role for not-for-profit organizations.

Authors:  Elin H Davies; Emma Fulton; Daniel Brook; Dyfrig A Hughes
Journal:  Br J Clin Pharmacol       Date:  2017-02-08       Impact factor: 4.335

3.  Expensive medicines: ensuring objective appraisal and equitable access.

Authors:  Suzanne R Hill; Lisa Bero; Geoff McColl; Elizabeth Roughead
Journal:  Bull World Health Organ       Date:  2015-01-01       Impact factor: 9.408

4.  Competing for public funding of medicines to treat rare disorders in New Zealand.

Authors:  Steffan Crausaz
Journal:  Bull World Health Organ       Date:  2015-02-01       Impact factor: 9.408

Review 5.  Cystic Fibrosis-Related Diabetes.

Authors:  Kayani Kayani; Raihan Mohammed; Hasan Mohiaddin
Journal:  Front Endocrinol (Lausanne)       Date:  2018-02-20       Impact factor: 5.555

Review 6.  Targeted therapies to improve CFTR function in cystic fibrosis.

Authors:  Malcolm Brodlie; Iram J Haq; Katie Roberts; J Stuart Elborn
Journal:  Genome Med       Date:  2015-09-24       Impact factor: 11.117

7.  Cystic Fibrosis: Breakthrough Drugs at Break-the-Bank Prices.

Authors:  David M Orenstein; Brian P O'Sullivan; Paul M Quinton
Journal:  Glob Adv Health Med       Date:  2015-11-01

8.  Game Changers.

Authors: 
Journal:  Ulster Med J       Date:  2015-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.